# Clinical Trials Data BRAF - Document 36

# Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors

## Clinical Trial: https://clinicaltrials.gov/study/NCT01878396

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors will be included. To determine the prevalence of CMC-positive patients in IV stage Melanoma, patients without mutated B-RAF undergoing chemotherapy and/or vaccines will be also enrolled at baseline, as part of study protocols approved and activated in the participating centers.\n\* Informed written consent.\n\nExclusion Criteria:\n\n\* Inadequate compliance to multiple blood draws (baseline, 15 days, 1th month, 4th month, and/or at progression) as scheduled in this adjunctive biologic study for patients carrying B-FAF mutation; inadequate compliance to adjunctive blood draws, as scheduled at baseline for BRAF wild-type\n\* Previously exposure to immunological treatment.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Primary care clinic",

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient with a BRAF gene mutation would indeed be eligible for the trial. The inclusion criteria specify that both patients with and without the mutated BRAF gene are to be enrolled, as long as they are undergoing the appropriate treatments (selective B-RAF inhibitors for those with the mutation, or chemotherapy and/or vaccines for those without the mutation). Therefore, a patient with a BRAF mutation, who is undergoing treatment with selective B-RAF inhibitors, meets the inclusion criteria for the trial.